Association of the Endotoxin Antagonist E5564 with High-Density Lipoproteins In Vitro: Dependence on Low-Density and Triglyceride-Rich Lipoprotein Concentrations

Similar Items

• Consequences of Interaction of a Lipophilic Endotoxin Antagonist with Plasma Lipoproteins
  od: Rose, Jeffrey R., i dr.
  Izdano: (2000)
• Lipoprotein Distribution of a Novel Endotoxin Antagonist, E5531, in Plasma from Human Subjects with Various Lipid Levels
  od: Wasan, Kishor M., i dr.
  Izdano: (1999)
• Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers
  od: Rossignol, Daniel P., i dr.
  Izdano: (2004)
• Plasma Lipoprotein Distribution of Liposomal Nystatin Is Influenced by Protein Content of High-Density Lipoproteins
  od: Cassidy, Shawn M., i dr.
  Izdano: (1998)
• Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: Studies with cyclosporine A
  od: Wasan, Kishor M., i dr.
  Izdano: (2002)